Skip to main content
Clinical Trials/ACTRN12614000865617
ACTRN12614000865617
Recruiting
未知

In healthy postmenopausal women, what are the effects of calcium citrate compared with a placebo on serum calcium, blood pressure and blood coagulation?

niversity of Auckland0 sites40 target enrollmentAugust 13, 2014

Overview

Phase
未知
Intervention
Not specified
Conditions
Cardiovascular disease
Sponsor
niversity of Auckland
Enrollment
40
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 13, 2014
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
niversity of Auckland

Eligibility Criteria

Inclusion Criteria

  • Female, postmenopausal 5 years or more (menopause defined as at least 12 months since last period in a woman aged \> 45 yrs with intact uterus, or serum oestradiol \< 100 pmol/l with FSH \> 50 IU/l in younger or hysterectomised women).

Exclusion Criteria

  • Current smoker, current use of Warfarin, aspirin or other blood thinning medications, diabetes, current use of blood pressure medication, past history of coronary heart disease, cerebrovascular disease or peripheral vascular disease, renal impairment (serum creatinine \>0\.15 mmol/L), chronic liver disease, untreated hypothyroidism or hyperthyroidism, concurrent major systemic illness, including malignancy, active major gastrointestinal disease, metabolic bone diseases, or serum ALP \>normal, primary hyperparathyroidism, calcium supplements: those consistently using 500 mg/day or more need to be off calcium supplements for 6 months before entering the study; doses \<100 mg/day can be continued during the study; doses between 100 and 499 mg/day require intermediate times of withdrawal prior to study entry, current or expected use of oral glucocorticoid drugs during the trial period, current or past use of bisphosphonate therapy in the preceding 2 years, use of hormone replacement therapy within the last 12 months, use of other medication known to cause osteoporosis or interfere with bone metabolism, calciferol supplements \> 2000 IU/day (lower doses can be continued during the study).

Outcomes

Primary Outcomes

Not specified

Similar Trials